Palmer Knight Co Has $7.66 Million Stake in Danaher Co. (NYSE:DHR)

Palmer Knight Co lifted its holdings in shares of Danaher Co. (NYSE:DHR) by 0.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,645 shares of the conglomerate’s stock after buying an additional 108 shares during the quarter. Danaher comprises approximately 3.7% of Palmer Knight Co’s investment portfolio, making the stock its 11th biggest holding. Palmer Knight Co’s holdings in Danaher were worth $7,657,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Cary Street Partners Investment Advisory LLC grew its holdings in Danaher by 20.2% during the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after purchasing an additional 1,533 shares during the period. Caden Capital Partners LP grew its holdings in Danaher by 12.4% during the fourth quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock valued at $32,172,000 after purchasing an additional 15,313 shares during the period. JARISLOWSKY FRASER Ltd grew its holdings in Danaher by 10.8% during the fourth quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock valued at $132,524,000 after purchasing an additional 55,908 shares during the period. HighPoint Advisor Group LLC acquired a new position in Danaher during the fourth quarter valued at approximately $2,614,000. Finally, Norden Group LLC acquired a new position in Danaher during the first quarter valued at approximately $4,151,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 1.7 %

Shares of DHR stock traded up $4.56 during trading on Friday, reaching $269.27. The company’s stock had a trading volume of 249,452 shares, compared to its average volume of 2,773,118. The company has a market cap of $199.44 billion, a price-to-earnings ratio of 45.52, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The business has a fifty day moving average price of $260.98 and a 200-day moving average price of $255.61. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same period in the previous year, the company earned $2.05 earnings per share. Analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 over the last ninety days. Insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on DHR shares. Jefferies Financial Group started coverage on shares of Danaher in a report on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 price target on shares of Danaher in a research note on Friday. Robert W. Baird lifted their price target on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Finally, Barclays lifted their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $278.94.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.